AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00425763 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AQAS
Description: AQAS dosed by body weight, on days 0, 1, 2
Study NCT01570114 — intervention group
Intervention type: DEVICE
Intervention: Fully covered metallic colonic stent
Description: Endoscopically insertion of fully covered metallic colonic stent
Study NCT01509274 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Plasma
Description: 3 ml plasma injected once into the plantar fascia
Study NCT01509274 — intervention group
Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Saline
Description: 3 ml of saline injected once into the plantar fascia
Study NCT01509274 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy + heel cap
Description: Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
Study NCT00931645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation
Description: TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
Study NCT00931645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: DHAP rescue and Autologous stem cell transplantation
Description: DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
Study NCT00931645 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: DHAP rescue and F+C
Description: DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) \& cyclophosphamide (300 mg/sqm)
Study NCT01587287 — intervention group
Intervention type: DEVICE
Intervention: Corneal power measurement
Description: All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
Study NCT02658760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: dexmedetomidine plus placebo
Study NCT02658760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: dexmedetomidine and Bupivacaine
Study NCT02658760 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: dexmedetomidine and Bupivacaine
Study NCT02792920 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: CoCr-EES
Study NCT03242525 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POCT and central laboratory blood analysis
Description: In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
Study NCT00743717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: zirconia femoral component
Description: total knee arthroplasty performed using implant with zirconia femoral component
Study NCT00743717 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cobalt chrome femoral component
Description: total knee arthroplasty performed using implant with cobalt chrome femoral component
Study NCT01516918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-222
Description: tablet, 400-mg twice daily
Study NCT01516918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir
Description: tablet, 1125-mg twice daily
Study NCT01516918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: tablet, 1000-mg per day for subjects weighing \<75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
Study NCT01516918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon-alfa-2a
Description: subcutaneous injection, 180-mcg, once weekly
Study NCT01478373 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib (TKI258)
Description: Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
Study NCT03560128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endocuff Vision device
Description: Subjects randomized to undergo a colonoscopy procedure with the Endocuff Vision device will have this device placed on the colonoscope used during their procedure.
Study NCT03560128 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AmplifEYE device
Description: Subjects randomized to undergo a colonoscopy procedure with the AmplifEYE device will have this device placed on the colonoscope used during their procedure.
Study NCT00919126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
Study NCT00919126 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xenon
Description: Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
Study NCT00919126 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medical Air in Oxygen
Description: Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
Study NCT01108380 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.
Study NCT01108380 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.
Study NCT01108380 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Plasma pheresis, Right portal vein embolization
Description: Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.~Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam.
Study NCT01734759 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taste Test
Description: Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.~Medications to be sampled and the corresponding dose of the test dose are:~* Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg~* Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg~* Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg~* Steroids: prednisolone 1.5 mg, prednisone 0.5 mg~* H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg
Study NCT03450265 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Description: Applied according to the current instruction for use (IFU). According to the IFU, a maximum of 7 Hemopatch 45 x 90 mm patches can be used in adults.
Study NCT00637494 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mifepristone
Description: 1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
Study NCT00637494 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
Study NCT03028116 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:~NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
Study NCT03028116 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: water for injection
Study NCT01301729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
Study NCT01301729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
Study NCT01301729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: 4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: FP
Description: ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LABA
Description: LABA will be administered as per investigator discretion.
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LTRA
Description: LTRA will be administered as per investigator discretion.
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: LAMA
Description: LAMA will be administered as per investigator discretion.
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Theophylline
Description: Theophylline will be administered as per investigator discretion.
Study NCT03450265 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tachosil
Description: Applied according to the current instruction for use (IFU).
Study NCT02537691 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Oral Corticosteroids
Description: Oral corticosteroids will be administered as per investigator discretion.
Study NCT04151043 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Suggestions
Description: Verbal suggestions or no suggestions about treatment outcome
Study NCT04151043 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Deep brain stimulation
Description: Regulation of deep brain stimulation intensity
Study NCT01920529 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
Study NCT01920529 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: aerobic exercise
Description: Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
Study NCT00971373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Vestagen scrubs
Description: antimicrobial impregnated textile
Study NCT01372748 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard CPR
Description: 30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
Study NCT01372748 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous chest compressions
Description: Continuous chest compressions during the first 6 minutes of the resuscitation.
Study NCT01281605 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Active titration algorithm
Description: Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(\<110mg/dl).
Study NCT01281605 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual titration algorithm
Description: All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG \< 70 mg/dL.
Study NCT01377818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ventilation
Description: positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.~Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night).
Study NCT01377818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: excecise training
Description: The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:~* 20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.~* Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)
Study NCT01377818 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Both
Description: both types of intervention
Study NCT04197778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DDO-3055 tablet
Description: DDO-3055 tablet, 2 single doses separated by 6 days.
Study NCT04327011 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toca 511 vector
Description: Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
Study NCT04327011 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toca FC • Flucytosine • 5-FC • 5-Fluorocytosine
Description: Toca FC is an extended-release formulation of flucytosine.
Study NCT00262665 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ORG 24448
Description: flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Study NCT00262665 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
Study NCT02964312 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nasal Implant
Description: Latera implant placed as a standalone procedure or in conjunction with a turbinate reduction procedure in an office setting under local anesthesia.
Study NCT01295398 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nebulisations
Study NCT01295398 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: nebulisations
Study NCT03719027 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Study population
Description: Dyspnea assessment (NYHA functional class) EKG Echocardiography
Study NCT02451761 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood sampling
Study NCT01819870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dilatrend SR capsule 32mg
Description: * 1 capsule, oral, once daily, 7days~* over the period I\&II(crossover)
Study NCT01819870 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dilatrend IR tablet 25mg
Description: * 1 tablet, oral, once daily, 7days~* over the period I\&II(crossover)
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Moxifloxacin
Description: Single dose placebo oral tablet Moxifloxacin
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Single oral dose tablet Moxifloxacin (400mg)
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/Vilanterol 125/25mcg
Description: Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: Single inhalation from GSK573719 500mcg DPI once daily
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719/Vilanterol 500/100mcg
Description: Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo DPI
Description: Single Inhalation from matching Placebo DPI once daily
Study NCT01521377 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo DPI
Description: Single Inhalation from matching Placebo DPI once daily
Study NCT03424603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STRO-001
Description: intravenous antibody drug conjugate
Study NCT01201226 — intervention group
Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Removal of half an ovary
Description: Removal of half an ovary
Study NCT01248637 — intervention group
Intervention type: DRUG
Intervention: Pimonidazole hydrochloride
Description: Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 \<= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
Study NCT02253784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Study NCT02253784 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Study NCT01630889 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roxadustat
Description: Oral capsule
Study NCT00486382 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Leish-111f + MPL-SE Adjuvant
Study NCT03217214 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Thermography
Description: Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
Study NCT02974842 — intervention group
Intervention type: DEVICE
Intervention: MAKO 7
Description: Hysteroscopic cell sampling
Study NCT03968848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acalabrutinib
Description: A 50-mg single oral dose of acalabrutinib will be administered.
Study NCT03262467 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)
Description: In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
Study NCT03262467 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)
Description: In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
Study NCT00848224 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: systems-based and pharmacist-mediated program
Description: Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
Study NCT01854424 — intervention group
Intervention type: OTHER
Intervention: Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.
Description: All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.